Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS)

Business Insider

a day ago

In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Evolus (EOLS – Research Report), with a price target of $25.00. The company's shares closed yesterday at $10.24.
Confident Investing Starts Here:
Ear covers the Healthcare sector, focusing on stocks such as Evolus, Tectonic Therapeutic, and Arcutis Biotherapeutics. According to TipRanks, Ear has an average return of -3.1% and a 37.56% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus with a $24.00 average price target, which is a 134.38% upside from current levels. In a report released on May 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $25.00 price target.
Based on Evolus' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $68.07 million and a GAAP net loss of $18.89 million. In comparison, last year the company earned a revenue of $59.33 million and had a GAAP net loss of $13.11 million
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Albert White, a Director at EOLS bought 20,000.00 shares for a total of $189,000.00.